Abb.: Tosoh

How to purify and analyze your antibodies efficiently

Chromatography methods and practical tips to simplify and reduce the costs of your processes

Read more
© Abivax

Abivax bags €36m fund for COVID-19 programme

French Abivax SA has received a €36m non-dilutive funding from Bpifrance for its ABX464 Covid-19 programme.

Read more
4Teen4's antibody procizumab might be a way not not only resueing patients with cardiogenic shock and burns from organ failure but also patients with other conditions caused by massive cell death such as COVID-19-triggered ARDS. © 4Teen4 Pharmaceuticals GmbH

4Teen4’s DPP3 predicts burn mortality

4TEEN4 Pharmaceuticals GmbH published data suggesting that high plasma levels of dipeptidyl peptidase 3 were indicative for upcoming multiple organ failure in burn patients.

Read more

Genentech: New Head of Research and Early Development

Aviv Regev will follow Michael Varney as Head of Genentech Research and Early Development (gRED) at Roche subsidiary Genentech. Varney will retire from the company at the end of July.

Read more
ACIB/Ionophore

IMI ramps up COVID fund

The funding pot of the Innovation Medicines Initiative has been boosted to €117m. IMI has also selected eight projects to fund.

Read more
Austrian start-up Rebel Meat presented its hybrid meat balls during the EFIB 2019 conference in Brussels. Source: EFIB 2019

Growing interest in alternative meat market

Manufacturers are keen to get involved in the alternative meat market. Investors and incubators are pushing forward start-ups.

Read more
Mosa Meat aims at producing a cultured meat hamburger by 2022. Source: Mosa Meat

Upscaling in the race to cultured meat

A first wave of cultured meat companies is pushing forward. European start-ups such as Mosa Meat and Peace of Meat are part of the game.

Read more

New CEO at Deinove

Montpellier-based Deinove has named a new Chief Executive Officer. Alexis Rideau took over the helm of the company in the beginning of May.

Read more
University of Goergia researchers have decribed the shielded versions of the viral S-protein. a. Side view (upper panels) and Top view (lower panels) of the SARS-CoV-2 S protein (grey surface) with homogeneous Complex glycosylation (magenta) showing aligned antibody fragments (ribbons) from co-complexes with the S glycoproteins from SARS-CoV-1 (orange) and MERS (cyan) 48,50-61 . b. Glycans present on SARS-CoV-2 S glycoprotein that are incompatible with known antibody positions due to steric overlap are shown in yellow. a. Side view (upper panels) of the SARS-CoV-2 S protein (grey) with homogeneous complex glycosylation (magenta) showing aligned antibody fragments (ribbons) from co-complexes with the S glycoproteins from SARS-CoV-1 (orange) and MERS (cyan). b. Glycans present on SARS-CoV-2 S glycoprotein that are incompatible with known antibody positions due to steric overlap are shown in yellow. c. Potential antibody poses after elimination of epitopes blocked by S protein glycosylation. © Doi: 10.1101/2020.04.07.030445

S-Protein: Glycosylation pattern revealed

British researchers have deciphered the glycosylation pattern of the viral spike protein of SARS-CoV-2 laying the foundation for vaccine development.

Read more
© ElisaRiva/pixabay.com

Newron terminates sarizotan development in Rett syndrome

Newron Pharmaceuticals S.p.A.‘s Sarizotan failed to meet efficacy endpoints in the Phase III STARS study.

Read more